(Q36600380)

15 August 2017

1 reference

title

Aiming to induce broadly reactive neutralizing antibody responses with HIV-1 vaccine candidates. (English)

1 reference

15 August 2017

1 reference

1 reference

2

David C Montefiori

1 reference

15 August 2017

1

Barton F Haynes

1 reference

15 August 2017

publication date

1 August 2006

1 reference

Expert Review of Vaccines

15 August 2017

published in

1 reference

15 August 2017

volume

5

1 reference

15 August 2017

issue

4

1 reference

15 August 2017

page(s)

579-595

1 reference

Medicine. The need for a global HIV vaccine enterprise

15 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.4.579

Progress toward an HIV vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.4.579

Immunologic control of HIV-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.4.579

The potential roles of 4-1BB costimulation in HIV type 1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.4.579

Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai Project Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.4.579

Neutralizing antibody directed against the HIV-1 envelope glycoprotein can completely block HIV-1/SIV chimeric virus infections of macaque monkeys.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.4.579

Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.4.579

Antibody protects macaques against vaginal challenge with a pathogenic R5 simian/human immunodeficiency virus at serum levels giving complete neutralization in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.4.579

Potent cross-group neutralization of primary human immunodeficiency virus isolates with monoclonal antibodies--implications for acquired immunodeficiency syndrome vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.4.579

Antibody vs. HIV in a clash of evolutionary titans

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.4.579

Initial studies on active immunization of HIV-infected subjects using a gp120-depleted HIV-1 Immunogen: long-term follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.4.579

Evaluation of the safety, immunogenicity, and protective efficacy of whole inactivated simian immunodeficiency virus (SIV) vaccines with conformationally and functionally intact envelope glycoproteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.4.579

Live attenuated HIV vaccines: pitfalls and prospects

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.4.579

HIV vaccine design: insights from live attenuated SIV vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.4.579

Envelope-constrained neutralization-sensitive HIV-1 after heterosexual transmission

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.4.579

Characterization of human immunodeficiency virus type 1 (HIV-1) envelope variation and neutralizing antibody responses during transmission of HIV-1 subtype B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.4.579

Selection for human immunodeficiency virus type 1 envelope glycosylation variants with shorter V1-V2 loop sequences occurs during transmission of certain genetic subtypes and may impact viral RNA levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.4.579

Stoichiometry of envelope glycoprotein trimers in the entry of human immunodeficiency virus type 1

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.4.579

Passive transfer studies to elucidate the role of antibody-mediated protection against HIV-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.4.579

Defining the Protective Antibody Response for HIV-1

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.4.579

Dual-subtype vaccine (Fel-O-Vax FIV) protects cats against contact challenge with heterologous subtype B FIV infected cats

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.4.579

Immunization with recombinant canarypox vectors expressing membrane-anchored glycoprotein 120 followed by glycoprotein 160 boosting fails to generate antibodies that neutralize R5 primary isolates of human immunodeficiency virus type 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.4.579

Immunization with envelope subunit vaccine products elicits neutralizing antibodies against laboratory-adapted but not primary isolates of human immunodeficiency virus type 1. The National Institute of Allergy and Infectious Diseases AIDS Vaccine Ev

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.4.579

Correlation between immunologic responses to a recombinant glycoprotein 120 vaccine and incidence of HIV-1 infection in a phase 3 HIV-1 preventive vaccine trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.4.579

Augmentation of human immunodeficiency virus type 1 neutralizing antibody by priming with gp160 recombinant vaccinia and boosting with rgp160 in vaccinia-naive adults. The NIAID AIDS Vaccine Clinical Trials Network

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.4.579

A canarypox vaccine expressing multiple human immunodeficiency virus type 1 genes given alone or with rgp120 elicits broad and durable CD8+ cytotoxic T lymphocyte responses in seronegative volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.4.579

Induction of immune responses to HIV-1 by canarypox virus (ALVAC) HIV-1 and gp120 SF-2 recombinant vaccines in uninfected volunteers. NIAID AIDS Vaccine Evaluation Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.4.579

Cellular and humoral immune responses to a canarypox vaccine containing human immunodeficiency virus type 1 Env, Gag, and Pro in combination with rgp120.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.4.579

Recombinant modified vaccinia virus ankara expressing the surface gp120 of simian immunodeficiency virus (SIV) primes for a rapid neutralizing antibody response to SIV infection in macaques

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.4.579

Priming B cell-mediated anti-HIV envelope responses by vaccination allows for the long-term control of infection in macaques exposed to a R5-tropic SHIV.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.4.579

An effective AIDS vaccine based on live attenuated vesicular stomatitis virus recombinants

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.4.579

Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.4.579

Reduction of simian-human immunodeficiency virus 89.6P viremia in rhesus monkeys by recombinant modified vaccinia virus Ankara vaccination

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.4.579

Vaccination of macaques against pathogenic simian immunodeficiency virus with Venezuelan equine encephalitis virus replicon particles

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.4.579

Enhanced immunogenicity of gp120 protein when combined with recombinant DNA priming to generate antibodies that neutralize the JR-FL primary isolate of human immunodeficiency virus type 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.4.579

Neutralizing antibodies elicited by immunization of monkeys with DNA plasmids and recombinant adenoviral vectors expressing human immunodeficiency virus type 1 proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.4.579

Long-term memory B-cell responses in recipients of candidate human immunodeficiency virus type 1 vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.4.579

Neutralizing antibodies associated with viremia control in a subset of individuals after treatment of acute human immunodeficiency virus type 1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.4.579

Nature of nonfunctional envelope proteins on the surface of human immunodeficiency virus type 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.4.579

Role of complement and Fc receptors in the pathogenesis of HIV-1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.4.579

Antibody-dependent cellular cytotoxicity independently predicts survival in severely immunocompromised human immunodeficiency virus-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.4.579

Antibody from patients with acute human immunodeficiency virus (HIV) infection inhibits primary strains of HIV type 1 in the presence of natural-killer effector cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.4.579

Recommendations for the design and use of standard virus panels to assess neutralizing antibody responses elicited by candidate human immunodeficiency virus type 1 vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.4.579

Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.4.579

Structure of an unliganded simian immunodeficiency virus gp120 core

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.4.579

Mechanisms of viral membrane fusion and its inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.4.579

Enfuvirtide: the first therapy to inhibit the entry of HIV-1 into host CD4 lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.4.579

Antibody neutralization and escape by HIV-1

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.4.579

Rapid evolution of the neutralizing antibody response to HIV type 1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.4.579

Neutralizing antibody responses drive the evolution of human immunodeficiency virus type 1 envelope during recent HIV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.4.579

HIV-1 evades antibody-mediated neutralization through conformational masking of receptor-binding sites

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.4.579

The broadly neutralizing anti-human immunodeficiency virus type 1 antibody 2G12 recognizes a cluster of alpha1-->2 mannose residues on the outer face of gp120.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.4.579

Dissection of the carbohydrate specificity of the broadly neutralizing anti-HIV-1 antibody 2G12.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.4.579

Impact of natural sequence variation in the V2 region of the envelope protein of human immunodeficiency virus type 1 on syncytium induction: a mutational analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.4.579

Cooperation of the V1/V2 and V3 domains of human immunodeficiency virus type 1 gp120 for interaction with the CXCR4 receptor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.4.579

Father-to-mother-to-infant transmission of HIV-1: clonally transmitted isolate of infant mutates more rapidly than that of the mother and rapidly loses reactivity with neutralizing antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.4.579

Type-specific neutralization of the human immunodeficiency virus with antibodies to env-encoded synthetic peptides

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.4.579

The v3 loop is accessible on the surface of most human immunodeficiency virus type 1 primary isolates and serves as a neutralization epitope.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.4.579

Identifying epitopes of HIV-1 that induce protective antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.4.579

Antibodies that inhibit fusion of human immunodeficiency virus-infected cells bind a 24-amino acid sequence of the viral envelope, gp120

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.4.579

Broadly neutralizing antibodies elicited by the hypervariable neutralizing determinant of HIV-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.4.579

Type-Restricted Neutralization of Molecular Clones of Human Immunodeficiency Virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.4.579

Dilemma of neutralization resistance of HIV-1 field isolates and vaccine development.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.4.579

Analysis of HIV-1 subtype B third variable region peptide motifs for induction of neutralizing antibodies against HIV-1 primary isolates

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.4.579

Comprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.4.579

Antibodies that are cross-reactive for human immunodeficiency virus type 1 clade a and clade B v3 domains are common in patient sera from Cameroon, but their neutralization activity is usually restricted by epitope masking

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.4.579

Diversity considerations in HIV-1 vaccine selection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.4.579

Structure of a V3-containing HIV-1 gp120 core

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.4.579

The impact of envelope glycoprotein cleavage on the antigenicity, infectivity, and neutralization sensitivity of Env-pseudotyped human immunodeficiency virus type 1 particles

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.4.579

The C108g epitope in the V2 domain of gp120 functions as a potent neutralization target when introduced into envelope proteins derived from human immunodeficiency virus type 1 primary isolates.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.4.579

Characterization and epitope mapping of neutralizing monoclonal antibodies produced by immunization with oligomeric simian immunodeficiency virus envelope protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.4.579

Potent neutralization of primary HIV-1 isolates by antibodies directed against epitopes present in the V1/V2 domain of HIV-1 gp120.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.4.579

Characterization of neutralizing sites in the second variable and fourth variable region in gp125 and a conserved region in gp36 of human immunodeficiency virus type 2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.4.579

Influence of N-linked glycans in V4-V5 region of human immunodeficiency virus type 1 glycoprotein gp160 on induction of a virus-neutralizing humoral response

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.4.579

The V1/V2 domain of gp120 is a global regulator of the sensitivity of primary human immunodeficiency virus type 1 isolates to neutralization by antibodies commonly induced upon infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.4.579

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.4.579

Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.4.579

Cardiolipin polyspecific autoreactivity in two broadly neutralizing HIV-1 antibodies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.4.579

Immunofocusing: antigen engineering to promote the induction of HIV-neutralizing antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.4.579

Improved design of an antigen with enhanced specificity for the broadly HIV-neutralizing antibody b12.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.4.579

Comparing antigenicity and immunogenicity of engineered gp120.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.4.579

Antigenic conservation and immunogenicity of the HIV coreceptor binding site

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.4.579

Access of antibody molecules to the conserved coreceptor binding site on glycoprotein gp120 is sterically restricted on primary human immunodeficiency virus type 1

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.4.579

Relationships between CD4 independence, neutralization sensitivity, and exposure of a CD4-induced epitope in a human immunodeficiency virus type 1 envelope protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.4.579

Neutralization of divergent human immunodeficiency virus type 1 variants and primary isolates by IAM-41-2F5, an anti-gp41 human monoclonal antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.4.579

A potent cross-clade neutralizing human monoclonal antibody against a novel epitope on gp41 of human immunodeficiency virus type 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.4.579

Broadly neutralizing antibodies targeted to the membrane-proximal external region of human immunodeficiency virus type 1 glycoprotein gp41.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.4.579

Structure and mechanistic analysis of the anti-human immunodeficiency virus type 1 antibody 2F5 in complex with its gp41 epitope

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.4.579

Broadly neutralizing anti-HIV antibody 4E10 recognizes a helical conformation of a highly conserved fusion-associated motif in gp41

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.4.579

HIV vaccine design and the neutralizing antibody problem

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.4.579

Enfuvirtide (T-20) cross-reactive glycoprotein 41 antibody does not impair the efficacy or safety of enfuvirtide

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.4.579

Anti-human immunodeficiency virus type 1 (HIV-1) antibodies 2F5 and 4E10 require surprisingly few crucial residues in the membrane-proximal external region of glycoprotein gp41 to neutralize HIV-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.4.579

Dissection of human immunodeficiency virus type 1 entry with neutralizing antibodies to gp41 fusion intermediates

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.4.579

Exclusion of HIV epitopes shared with human proteins is prerequisite for designing safer AIDS vaccines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.4.579

Signaling in transitional type 2 B cells is critical for peripheral B-cell development

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.4.579

A checkpoint for autoreactivity in human IgM+ memory B cell development

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.4.579

Predictive value of anti-cell and anti-human immunodeficiency virus (HIV) humoral responses in HIV-1-exposed seronegative cohorts of European and Asian origin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.4.579

Immunogenicity and protective efficacy of recombinant human T-cell leukemia/lymphoma virus type 1 NYVAC and naked DNA vaccine candidates in squirrel monkeys (Saimiri sciureus).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.4.579

Assembly, structure, and antigenic properties of virus-like particles rich in HIV-1 envelope gp120.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.4.579

Solid-phase proteoliposomes containing human immunodeficiency virus envelope glycoproteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.4.579

HIV mucosal vaccine: nasal immunization with gp160-encapsulated hemagglutinating virus of Japan-liposome induces antigen-specific CTLs and neutralizing antibody responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.4.579

Detection of anti-human cell antibodies in sera from macaques immunized with whole inactivated virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.4.579

Induction of neutralizing antibodies against human immunodeficiency virus type 1 primary isolates by Gag-Env pseudovirion immunization

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.4.579

Stabilization of the soluble, cleaved, trimeric form of the envelope glycoprotein complex of human immunodeficiency virus type 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.4.579

Characterization of stable, soluble trimers containing complete ectodomains of human immunodeficiency virus type 1 envelope glycoproteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.4.579

Modifications that stabilize human immunodeficiency virus envelope glycoprotein trimers in solution

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.4.579

Evaluating the immunogenicity of a disulfide-stabilized, cleaved, trimeric form of the envelope glycoprotein complex of human immunodeficiency virus type 1

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.4.579

Improved elicitation of neutralizing antibodies against primary human immunodeficiency viruses by soluble stabilized envelope glycoprotein trimers

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.4.579

Comparison of HIV Type 1 ADA gp120 monomers versus gp140 trimers as immunogens for the induction of neutralizing antibodies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.4.579

Enhanced immunogenicity of a human immunodeficiency virus type 1 env DNA vaccine by manipulating N-glycosylation signals. Effects of elimination of the V3 N306 glycan

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.4.579

Role of N-linked glycans in a human immunodeficiency virus envelope glycoprotein: effects on protein function and the neutralizing antibody response

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.4.579

A role for carbohydrates in immune evasion in AIDS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.4.579

Influence of glycosylation on the efficacy of an Env-based vaccine against simian immunodeficiency virus SIVmac239 in a macaque AIDS model

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.4.579

The ability of an oligomeric human immunodeficiency virus type 1 (HIV-1) envelope antigen to elicit neutralizing antibodies against primary HIV-1 isolates is improved following partial deletion of the second hypervariable region

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.4.579

DNA vaccination with the human immunodeficiency virus type 1 SF162DeltaV2 envelope elicits immune responses that offer partial protection from simian/human immunodeficiency virus infection to CD8(+) T-cell-depleted rhesus macaques

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.4.579

Effect of partial and complete variable loop deletions of the human immunodeficiency virus type 1 envelope glycoprotein on the breadth of gp160-specific immune responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.4.579

Immunogenicity and ability of variable loop-deleted human immunodeficiency virus type 1 envelope glycoproteins to elicit neutralizing antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.4.579

Changes in the immunogenic properties of soluble gp140 human immunodeficiency virus envelope constructs upon partial deletion of the second hypervariable region

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.4.579

Expression and characterization of a single-chain polypeptide analogue of the human immunodeficiency virus type 1 gp120-CD4 receptor complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.4.579

Covalently crosslinked complexes of human immunodeficiency virus type 1 (HIV-1) gp120 and CD4 receptor elicit a neutralizing immune response that includes antibodies selective for primary virus isolates

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.4.579

Crosslinked HIV-1 envelope-CD4 receptor complexes elicit broadly cross-reactive neutralizing antibodies in rhesus macaques

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.4.579

Characterization of gp120 and its single-chain derivatives, gp120-CD4D12 and gp120-M9: implications for targeting the CD4i epitope in human immunodeficiency virus vaccine design

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.4.579

Immunogenicity of constrained monoclonal antibody A32-human immunodeficiency virus (HIV) Env gp120 complexes compared to that of recombinant HIV type 1 gp120 envelope glycoproteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.4.579

Antigenicity and immunogenicity of the HIV-1 gp41 epitope ELDKWA inserted into permissive sites of the MalE protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.4.579

Immunogenic presentation of a conserved gp41 epitope of human immunodeficiency virus type 1 on recombinant surface antigen of hepatitis B virus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.4.579

Enhancement of alpha -helicity in the HIV-1 inhibitory peptide DP178 leads to an increased affinity for human monoclonal antibody 2F5 but does not elicit neutralizing responses in vitro. Implications for vaccine design

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.4.579

Epitope insertion into variable loops of HIV-1 gp120 as a potential means to improve immunogenicity of viral envelope protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.4.579

Identification and characterization of a peptide that specifically binds the human, broadly neutralizing anti-human immunodeficiency virus type 1 antibody b12

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.4.579

Regional clustering of shared neutralization determinants on primary isolates of clade C human immunodeficiency virus type 1 from South Africa

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.4.579

Synergistic interaction between ligands binding to the CD4 binding site and V3 domain of human immunodeficiency virus type I gp120

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.4.579

Synergistic neutralization of HIV-1 by human monoclonal antibodies against the V3 loop and the CD4-binding site of gp120

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.4.579

Synergistic inhibition of HIV-1 by CD4 binding domain reagents and V3-directed monoclonal antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.4.579

V3-specific neutralizing antibodies in sera from HIV-1 gp160-immunized volunteers block virus fusion and act synergistically with human monoclonal antibody to the conformation-dependent CD4 binding site of gp120. NIH-NIAID AIDS Vaccine Clinical Tria

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.4.579

Neutralization synergy of human immunodeficiency virus type 1 primary isolates by cocktails of broadly neutralizing antibodies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.4.579

Improved breadth and potency of an HIV-1-neutralizing human single-chain antibody by random mutagenesis and sequential antigen panning

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.4.579

In vitro evolution of a neutralizing human antibody to human immunodeficiency virus type 1 to enhance affinity and broaden strain cross-reactivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.4.579

CDR walking mutagenesis for the affinity maturation of a potent human anti-HIV-1 antibody into the picomolar range

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.4.579

Polyvalent envelope glycoprotein vaccine elicits a broader neutralizing antibody response but is unable to provide sterilizing protection against heterologous Simian/human immunodeficiency virus infection in pigtailed macaques

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.4.579

Multi-envelope HIV-1 vaccine devoid of SIV components controls disease in macaques challenged with heterologous pathogenic SHIV.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.4.579

Human Immunodeficiency Virus Type 1 Subtype B Ancestral Envelope Protein Is Functional and Elicits Neutralizing Antibodies in Rabbits Similar to Those Elicited by a Circulating Subtype B Envelope

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.4.579

Antigenicity and immunogenicity of a synthetic human immunodeficiency virus type 1 group m consensus envelope glycoprotein

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.4.579

Hyperglycosylated Mutants of Human Immunodeficiency Virus (HIV) Type 1 Monomeric gp120 as Novel Antigens for HIV Vaccine Design

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.4.579

Variable-loop-deleted variants of the human immunodeficiency virus type 1 envelope glycoprotein can be stabilized by an intermolecular disulfide bond between the gp120 and gp41 subunits

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.4.579

Purification, Characterization, and Immunogenicity of a Soluble Trimeric Envelope Protein Containing a Partial Deletion of the V2 Loop Derived from SF162, an R5-Tropic Human Immunodeficiency Virus Type 1 Isolate

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.4.579

Synthetic vaccines: the role of adjuvants in immune targeting

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.4.579

Signal transduction pathways mediated by the interaction of CpG DNA with Toll-like receptor 9

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.4.579

Taking a Toll on human disease: Toll-like receptor 4 agonists as vaccine adjuvants and monotherapeutic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.4.579

Pleiotropic function of Toll-like receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.4.579

Progress in drug development of immunostimulatory CpG oligodeoxynucleotide ligands for TLR9.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.4.579

Adjuvant and antigen delivery properties of virosomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.4.579

Lipid-based self-adjuvanting vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.4.579

New approaches to vaccine adjuvants: inhibiting the inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.4.579

Anti-CD25 antibody enhancement of vaccine-induced immunogenicity: increased durable cellular immunity with reduced immunodominance

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.4.579

QS-21 promotes an adjuvant effect allowing for reduced antigen dose during HIV-1 envelope subunit immmunization in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.4.579

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.4.579

Fusion-competent vaccines: broad neutralization of primary isolates of HIV

21 January 2018

1 reference

3 January 2024

https://opencitations.net/index/api/v1/citations/10.1126/SCIENCE.283.5400.357

Identifiers

DOI

10.1586/14760584.5.4.579

1 reference

15 August 2017

1 reference